Expanded human NK cells armed with CAR uncouple potent anti-tumor activity from off-tumor toxicity against solid tumors
Ana L. Portillo,Richard Hogg,Sophie M. Poznanski,Eduardo A. Rojas,Niamh J. Cashell,Joanne A. Hammill,Marianne V. Chew,Mira M. Shenouda,Tyrah M. Ritchie,Quynh T. Cao,Jeremy A. Hirota,Sukhbinder Dhesy-Thind,Jonathan L. Bramson,Ali A. Ashkar
DOI: https://doi.org/10.1016/j.isci.2021.102619
IF: 5.8
2021-06-01
iScience
Abstract:Despite the remarkable success of chimeric antigen receptor (CAR)-T cells against hematologic malignancies, severe off-tumor effects have constrained their use against solid tumors. Recently, CAR-engineered natural killer (NK) cells have emerged as an effective and safe alternative. Here, we demonstrate that HER2 CAR-expression in NK cells from healthy donors and patients with breast cancer potently enhances their anti-tumor functions against various HER2-expressing cancer cells, regardless of MHC class I expression. Moreover, HER2 CAR-NK cells exert higher cytotoxicity than donor-matched HER2 CAR-T cells against tumor targets. Importantly, unlike CAR-T cells, HER2 CAR-NK cells do not elicit enhanced cytotoxicity or inflammatory cytokine production against non-malignant human lung epithelial cells with basal HER2 expression. Further, HER2 CAR-NK cells maintain high cytotoxic function in the presence of immunosuppressive factors enriched in solid tumors. These results show that CAR-NK cells may be a highly potent and safe source of immunotherapy in the context of solid tumors.
multidisciplinary sciences